Top Stories
Company says the Phase III DASL-HiCaP study supports adding the drug to radiation and hormone therapy for patients at high risk of recurrence.
Phase III results from the VOLGA trial show significant survival gains with the two-drug regimen, though the rival Padcev-Keytruda combo sets a high competitive bar.
The biotech's stock gained more than 66% on its first day of trading.
The patient died of septic pneumonia the day after receiving a high dose of chemotherapy, and 44 days after receiving an infusion of CD19-directed CAR-T cell therapy zolacabtagene autoleucel.
The trio will work together to design adaptive clinical trials for Alzheimer's disease and other neurological conditions.
Conference News
Patients receiving durvalumab plus olaparib lived almost one year longer than patients treated with chemotherapy alone Study results were especially encouraging for patients with tumors with mismatch...
· New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgery· Twice as many patients remained free ...
Published: 23 Oct 2026Latest phase III data show no improvement in event-free survival with the addition of peri-operative durvalumab to standard therapyPractice-changing results from the NIAGARA tria...
Published: 23 Oct 2026Findings from the TALENT trial, the first neoadjuvant study of an antibody–drug conjugate therapy in HR-positive, HER2-low early breast cancer, are soberingTrastuzumab deruxtecan...
Published: 23 Oct 2026The STARBOARD study supports treatment intensification and reports a predictable safety profile for the combinationFinal analysis results of the STARBOARD trial have demonstrated...
